The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia

Research output: Contribution to journalArticleResearchpeer-review


Research indicates that soluble fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PLGF) have diagnostic and prognostic significance for women with preeclampsia. However, sparse research has studied these biomarkers in women with preexisting comorbidities such as chronic hypertension, diabetes mellitus, systemic lupus erythematosus and chronic kidney disease. We undertook a prospective longitudinal cohort study to compare the sFLT-1: PlGF ratio between women with and without comorbidities who did and did not go on to develop preeclampsia. We found that women with comorbidities may develop preeclampsia with a milder elevation in sFLT-1: PlGF than do women without comorbidities. This has clinical and research implications.

Original languageEnglish
Pages (from-to)98-100
Number of pages3
JournalPregnancy Hypertension
Publication statusPublished - Aug 2022


  • Angiogenic
  • Comorbidities
  • Placental growth factor
  • PlGF
  • Preeclampsia
  • sFLT-1
  • Soluble fms-like tyrosine kinase-1

Cite this